STOXIL Drug Patent Profile
✉ Email this page to a colleague
When do Stoxil patents expire, and when can generic versions of Stoxil launch?
Stoxil is a drug marketed by Glaxosmithkline and is included in two NDAs.
The generic ingredient in STOXIL is idoxuridine. There are two drug master file entries for this compound. Additional details are available on the idoxuridine profile page.
Summary for STOXIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Patent Applications: | 4,090 |
Formulation / Manufacturing: | see details |
DailyMed Link: | STOXIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for STOXIL
US Patents and Regulatory Information for STOXIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | STOXIL | idoxuridine | OINTMENT;OPHTHALMIC | 015868-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | STOXIL | idoxuridine | SOLUTION/DROPS;OPHTHALMIC | 013934-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |